OBJECTIVE: Morbidly obese patients frequently present with mood and anxiety disorders, which are often treated with serotonin reuptake inhibitors (SRIs). Having observed that patients treated with SRIs frequently relapse after Roux-en-Y gastric bypass surgery, the authors sought to assess whether SRI bioavailability is reduced postoperatively. METHOD: Twelve gastric bypass candidates treated with an SRI for primary mood or anxiety disorders were studied prospectively. Timed blood samples for SRI plasma levels were drawn for pharmacokinetic studies before surgery and 1, 6, and 12 months afterward. Maximum concentration, time to maximum concentration, and area under the concentration/time curve (AUC) were determined. RESULTS: In eight of the 12 patients, AUC values 1 month after surgery dropped to an average of 54% (SD=18) of preoperative levels (range=36%-80%); in six of these patients, AUC values returned to baseline levels (or greater) by 6 months. Four patients had an exacerbation of depressive symptoms, which resolved by 12 months in three of them. Three of the four patients had a reduced AUC level at 1 month and either gained weight or failed to lose weight between 6 and 12 months. Normalization of the AUC was associated with improvement in symptom scores. CONCLUSIONS: Patients taking SRIs in this study were at risk for reduced drug bioavailability 1 month after Roux-en-Y gastric bypass. The authors recommend close psychiatric monitoring after surgery.
OBJECTIVE: Morbidly obesepatients frequently present with mood and anxiety disorders, which are often treated with serotonin reuptake inhibitors (SRIs). Having observed that patients treated with SRIs frequently relapse after Roux-en-Y gastric bypass surgery, the authors sought to assess whether SRI bioavailability is reduced postoperatively. METHOD: Twelve gastric bypass candidates treated with an SRI for primary mood or anxiety disorders were studied prospectively. Timed blood samples for SRI plasma levels were drawn for pharmacokinetic studies before surgery and 1, 6, and 12 months afterward. Maximum concentration, time to maximum concentration, and area under the concentration/time curve (AUC) were determined. RESULTS: In eight of the 12 patients, AUC values 1 month after surgery dropped to an average of 54% (SD=18) of preoperative levels (range=36%-80%); in six of these patients, AUC values returned to baseline levels (or greater) by 6 months. Four patients had an exacerbation of depressive symptoms, which resolved by 12 months in three of them. Three of the four patients had a reduced AUC level at 1 month and either gained weight or failed to lose weight between 6 and 12 months. Normalization of the AUC was associated with improvement in symptom scores. CONCLUSIONS:Patients taking SRIs in this study were at risk for reduced drug bioavailability 1 month after Roux-en-Y gastric bypass. The authors recommend close psychiatric monitoring after surgery.
Authors: Raquel Sanchez-Santos; Maria J Del Barrio; Cándida Gonzalez; Carmen Madico; Isabel Terrado; Maria L Gordillo; Jordi Pujol; Pablo Moreno; Carlos Masdevall Journal: Obes Surg Date: 2006-05 Impact factor: 4.129
Authors: Katherine L Wisner; Barbara H Hanusa; James M Perel; Kathleen S Peindl; Catherine M Piontek; Dorothy K Y Sit; Robert L Findling; Eydie L Moses-Kolko Journal: J Clin Psychopharmacol Date: 2006-08 Impact factor: 3.153
Authors: David B Sarwer; Naomi I Cohn; Lauren M Gibbons; Leanne Magee; Canice E Crerand; Steven E Raper; Ernest F Rosato; Noel N Williams; Thomas A Wadden Journal: Obes Surg Date: 2004-10 Impact factor: 4.129
Authors: Seth J Concors; Brett L Ecker; Richard Maduka; Alyssa Furukawa; Steven E Raper; Daniel D Dempsey; Noel N Williams; Kristoffel R Dumon Journal: Curr Treat Options Neurol Date: 2016-01 Impact factor: 3.598
Authors: Jan Peter Yska; Susanne van der Linde; Véronique V Tapper; Jan A Apers; Marloes Emous; Erik R Totté; Bob Wilffert; Eric N van Roon Journal: Obes Surg Date: 2013-06 Impact factor: 4.129
Authors: Ted D Adams; Lance E Davidson; Sheldon E Litwin; Jaewhan Kim; Ronette L Kolotkin; M Nazeem Nanjee; Jonathan M Gutierrez; Sara J Frogley; Anna R Ibele; Eliot A Brinton; Paul N Hopkins; Rodrick McKinlay; Steven C Simper; Steven C Hunt Journal: N Engl J Med Date: 2017-09-21 Impact factor: 91.245
Authors: Lieke Mitrov-Winkelmolen; Marie-Christine W van Buul-Gast; Dingeman J Swank; Hans W P M Overdiek; Ron H N van Schaik; Daan J Touw Journal: Obes Surg Date: 2016-09 Impact factor: 4.129